PNC Financial Services Group
ABCL icon

PNC Financial Services Group’s AbCellera Biologics ABCL Stock Holding History

PNC Financial Services Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$592 – 4773
2024
Q2 		$592 Hold
200
– – ﹤0.01% 4507
2024
Q1 		$906 Hold
200
– – ﹤0.01% 4381
2023
Q4 		$1.14K Hold
200
– – ﹤0.01% 4290
2023
Q3 		$920 Hold
200
– – ﹤0.01% 4390
2023
Q2 		$1.29K Hold
200
– – ﹤0.01% 4466
2023
Q1 		$1.51K Hold
200
– – ﹤0.01% 4370
2022
Q4 		$2.03K Hold
200
– – ﹤0.01% 4249
2022
Q3 		$2K Hold
200
– – ﹤0.01% 4151
2022
Q2 		$2K Hold
200
– – ﹤0.01% 4170
2022
Q1 		$2K Hold
200
– – ﹤0.01% 4161
2021
Q4 		$3K Hold
200
– – ﹤0.01% 4057
2021
Q3 		$4K Buy
+200
New +$3.54K ﹤0.01% 3970

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PNC Financial Services Group's ABCL Position: Q3 2024 in Review

PNC Financial Services Group sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 200 shares — an estimated $592 sold.

PNC Financial Services Group first reported a position in ABCL in Q3 2021 and held it in 12 quarters. The position peaked at $4K in Q3 2021. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • PNC Financial Services Group reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 200 AbCellera Biologics shares in Q3 2024, an estimated $592.
  • PNC Financial Services Group first reported a position in AbCellera Biologics in Q3 2021 and held it in 12 quarters.
  • PNC Financial Services Group's AbCellera Biologics position peaked at $4K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.